STOCK TITAN

[8-K] QUEST DIAGNOSTICS INC Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Quest Diagnostics (DGX) filed an 8‑K stating it issued a press release announcing its results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1, dated October 21, 2025.

The filing falls under Item 2.02 (Results of Operations and Financial Condition). Quest Diagnostics’ common stock trades on the NYSE under the symbol DGX.

Quest Diagnostics (DGX) ha presentato una 8‑K comunicando di aver emesso un comunicato stampa che annuncia i suoi risultati per il trimestre conclusosi il 30 settembre 2025. L'azienda ha allegato il comunicato stampa come Exhibit 99.1, datato 21 ottobre 2025.

La compilazione rientra nell'Item 2.02 (Risultati operativi e situazione finanziaria). Le azioni ordinarie di Quest Diagnostics sono negoziate sul NYSE sotto il simbolo DGX.

Quest Diagnostics (DGX) presentó un 8‑K indicando que emitió un comunicado de prensa anunciando sus resultados para el trimestre terminado el 30 de septiembre de 2025. La empresa adjuntó el comunicado de prensa como Exhibit 99.1, con fecha del 21 de octubre de 2025.

La presentación corresponde al apartado Item 2.02 (Resultados de operaciones y situación financiera). Las acciones comunes de Quest Diagnostics se negocian en la NYSE con el símbolo DGX.

퀘스트 다이아스틱스( DGX )가 2025년 9월 30일 종료된 분기의 실적을 발표했다는 8-K를 제출했습니다. 회사는 Exhibit 99.1로 이 보도자료를 제출했으며, 날짜는 2025년 10월 21일입니다.

이 제출은 항목 2.02(영업실적 및 재무 상태)에 해당합니다. 퀘스트 다이아스틱스의 보통주는 NYSE에서 심볼 DGX로 거래됩니다.

Quest Diagnostics (DGX) a déposé un formulaire 8-K indiquant qu'il a publié un communiqué de presse annonçant ses résultats pour le trimestre clos le 30 septembre 2025. L'entreprise a fourni le communiqué de presse en tant que Exhibit 99.1, daté du 21 octobre 2025.

Le dépôt relève de l'article 2.02 (Résultats opérationnels et situation financière). L'action ordinaire de Quest Diagnostics est négociée sur le NYSE sous le symbole DGX.

Quest Diagnostics (DGX) hat eine 8-K eingereicht, in der mitgeteilt wird, dass eine Pressemitteilung veröffentlicht wurde, die die Ergebnisse für das Quartal zum 30. September 2025 ankündigt. Das Unternehmen hat die Pressemitteilung als Exhibit 99.1, datiert vom 21. Oktober 2025, beigefügt.

Die Einreichung fällt unter Punkt 2.02 (Ergebnisse der operativen Tätigkeit und Finanzlage). Quest Diagnostics' Stammaktien werden an der NYSE unter dem Symbol DGX gehandelt.

Quest Diagnostics (DGX) قد قدمت نموذج 8-K يفيد بإصدارها بياناً صحفياً يعلن عن نتائجها للربع المنتهي في 30 سبتمبر 2025. وقد زودت الشركة البيان الصحفي كـ Exhibit 99.1، المؤرخ في 21 أكتوبر 2025.

يُعد التقديم ضمن البند 2.02 (نتائج التشغيل والظروف المالية). أسهم Quest Diagnostics العادية تُتَداول في بورصة NYSE تحت الرمز DGX.

Quest Diagnostics (DGX) 已提交一份8-K,指出发布了新闻稿,宣布截至2025年9月30日的季度业绩。公司已将该新闻稿作为 Exhibit 99.1 提交,日期为2025年10月21日。

该披露属于事项 2.02(经营业绩与财务状况)。Quest Diagnostics 的普通股在NYSE交易,代码为 DGX

Positive
  • None.
Negative
  • None.

Quest Diagnostics (DGX) ha presentato una 8‑K comunicando di aver emesso un comunicato stampa che annuncia i suoi risultati per il trimestre conclusosi il 30 settembre 2025. L'azienda ha allegato il comunicato stampa come Exhibit 99.1, datato 21 ottobre 2025.

La compilazione rientra nell'Item 2.02 (Risultati operativi e situazione finanziaria). Le azioni ordinarie di Quest Diagnostics sono negoziate sul NYSE sotto il simbolo DGX.

Quest Diagnostics (DGX) presentó un 8‑K indicando que emitió un comunicado de prensa anunciando sus resultados para el trimestre terminado el 30 de septiembre de 2025. La empresa adjuntó el comunicado de prensa como Exhibit 99.1, con fecha del 21 de octubre de 2025.

La presentación corresponde al apartado Item 2.02 (Resultados de operaciones y situación financiera). Las acciones comunes de Quest Diagnostics se negocian en la NYSE con el símbolo DGX.

퀘스트 다이아스틱스( DGX )가 2025년 9월 30일 종료된 분기의 실적을 발표했다는 8-K를 제출했습니다. 회사는 Exhibit 99.1로 이 보도자료를 제출했으며, 날짜는 2025년 10월 21일입니다.

이 제출은 항목 2.02(영업실적 및 재무 상태)에 해당합니다. 퀘스트 다이아스틱스의 보통주는 NYSE에서 심볼 DGX로 거래됩니다.

Quest Diagnostics (DGX) a déposé un formulaire 8-K indiquant qu'il a publié un communiqué de presse annonçant ses résultats pour le trimestre clos le 30 septembre 2025. L'entreprise a fourni le communiqué de presse en tant que Exhibit 99.1, daté du 21 octobre 2025.

Le dépôt relève de l'article 2.02 (Résultats opérationnels et situation financière). L'action ordinaire de Quest Diagnostics est négociée sur le NYSE sous le symbole DGX.

Quest Diagnostics (DGX) hat eine 8-K eingereicht, in der mitgeteilt wird, dass eine Pressemitteilung veröffentlicht wurde, die die Ergebnisse für das Quartal zum 30. September 2025 ankündigt. Das Unternehmen hat die Pressemitteilung als Exhibit 99.1, datiert vom 21. Oktober 2025, beigefügt.

Die Einreichung fällt unter Punkt 2.02 (Ergebnisse der operativen Tätigkeit und Finanzlage). Quest Diagnostics' Stammaktien werden an der NYSE unter dem Symbol DGX gehandelt.

0001022079false00010220792025-10-212025-10-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): October 21, 2025
Quest Diagnostics Incorporated
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or other jurisdiction of incorporation)
001-1221516-1387862
(Commission File Number)(I.R.S. Employer Identification No.)
500 Plaza Drive
Secaucus, NJ07094
(Address of principal executive offices)(Zip Code)
(973)520-2700
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 Par ValueDGXNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 2.02. Results of Operations and Financial Condition

On October 21, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
    
Item 9.01. Financial Statements and Exhibits
d. Exhibit
99.1
Press release of Quest Diagnostics Incorporated dated October 21, 2025 announcing, among other things, its results for the quarter ended September 30, 2025.
104The cover page from this current report on Form 8-K, formatted in Inline XBRL.



Signature
    
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 21, 2025

QUEST DIAGNOSTICS INCORPORATED
By:/s/ Sean D. Mersten
Sean D. Mersten
Vice President and Corporate Secretary




FAQ

What did Quest Diagnostics (DGX) announce in this 8-K?

The company reported it issued a press release announcing results for the quarter ended September 30, 2025.

Which period does the announcement cover for DGX?

It covers the quarter ended September 30, 2025.

Where can I find the detailed results for DGX?

The detailed results are in the press release furnished as Exhibit 99.1.

What is the date of the press release for DGX?

The press release is dated October 21, 2025.

Which SEC item does this DGX filing reference?

Item 2.02: Results of Operations and Financial Condition.

What exchange and ticker does Quest Diagnostics use?

Common stock trades on the NYSE under the symbol DGX.
Quest Diagnostics Inc

NYSE:DGX

DGX Rankings

DGX Latest News

DGX Latest SEC Filings

DGX Stock Data

21.29B
110.74M
0.4%
99.16%
3.8%
Diagnostics & Research
Services-medical Laboratories
Link
United States
SECAUCUS